NeOnc Technologies Holdings, Inc., a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, has announced a significant milestone in its strategic partnership with Quazar Investment. The company has executed a Sub-License Agreement, transferring rights from NeOnc to its Abu Dhabi subsidiary, NuroCure, covering the UAE and the wider GCC and MENA regions for its innovative NEO100 and NEO212 treatments. This agreement is part of a larger $50 million equity investment and expansion plan into the MENA region, as outlined in a non-binding term sheet. The partnership aims to drive institutional capital, enhance market liquidity, and support the launch of clinical trials and infrastructure development across the region. The completion of this partnership is contingent upon meeting several conditions, including the legal establishment of NuroMENA and NuroCure in Abu Dhabi and finalizing necessary offering documents.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。